Ob/Gyn

Your Article Summary

See Latest Articles

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials
Journal of Clinical Oncology, 01/11/08

De Laurentiis M et al. - In a study to evaluate the efficacy, disease-free survival (DFS), and overall survival (OS) after incorporating taxanes into anthracycline-based regimens for early breast cancer (EBC), it was found that the addition of a taxane improves the DFS and OS of high-risk EBC patients

• Studies were retrieved by searching the PubMed database and the proceedings of major conferences
• Hazard ratios (HR) and 95% CIs were extracted for DFS and OS from each trial and pooled estimates were obtained using an inverse-variance model

• 13 studies were included in the meta-analysis of 22,903 patients
• The pooled HR estimate was 0.83 for DFS and 0.85 for OS
• Risk reduction was not influenced by the type of taxane, by estrogen receptor (ER) expression, by number of axillary metastases, or by patient's age/menopausal status
• Sensitivity analysis showed that taxanes given in combination with anthracyclines did not significantly improve OS
• The test for interaction showed that HR did not differ between the 2 schedules
• Taxane administration resulted in an absolute 5-year risk reduction of 5% for DFS and 3% for OS

Today in Breast...keeping you current

Receive free subspecialty "5-minute updates" via email

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
Clinical Cancer Research, 11/20/09

One hundred cases of abdominal-based free flaps in breast reconstruction. The impact of preoperative computed tomographic angiography
Journal of Plastic, Reconstructive & Aesthetic Surgery, 11/20/09

Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: A debated clinical issue
Gynecological Endocrinology, 11/20/09

 See all of Breast